Study 16 of 46 for search of: "Lymphedema"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area
This study has been completed.
Sponsors and Collaborators: Centers for Disease Control and Prevention
Procter and Gamble
Ste. Croix Hospital, Leogane, Haiti
Information provided by: Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT00139100
  Purpose

Introduction. Lymphatic filariasis is a devastating mosquito-transmitted parasitic disease that causes lymphedema or elephantiasis of the leg in 15 million persons, the majority of whom are women. In these persons, frequent bacterial infections ("acute attacks") of the legs adversely affect physical health, economic well-being, and quality of life. Prevention of bacterial infections through hygiene and skin care can result in significant improvements in lymphedema and patient well-being.

Methods. To determine the extent to which antibacterial soap can help reduce the incidence of acute bacterial infections of the lower limbs in persons with filarial lymphedema, 200 patients of the Ste. Croix Hospital lymphedema treatment clinic in Leogane, Haiti randomly assigned to receive either antibacterial (Safeguard) or placebo (Camay) soap and acute attacks monitored monthly for 12 months. Both groups received specific instructions on washing and skin care.


Condition Intervention
Lymphedema
Cellulitis
Drug: antimicrobial agent in soap

Genetics Home Reference related topics: lymphedema-distichiasis syndrome
MedlinePlus related topics: Antibiotics Bacterial Infections Cellulitis Lymphedema
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Efficacy Study
Official Title: Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis

Further study details as provided by Centers for Disease Control and Prevention:

Primary Outcome Measures:
  • Incidence of bacterial "acute attacks", assessed monthly.
  • Reported or observed severity of these acute attacks.
  • Duration of acute attacks.

Secondary Outcome Measures:
  • Process measures
  • Number of bars of soap used per patient per month.
  • Demonstrated knowledge and ability to wash leg appropriately during home visits.
  • Reported patient satisfaction with soap.
  • Reported frequency of leg washing.

Estimated Enrollment: 200
Study Start Date: February 2001
Estimated Study Completion Date: March 2002
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients eligible for participation include those who are currently enrolled in the lymphedema treatment program in Leogane who 1) have been trained in the techniques of self-care, 2) who live in a 10-km radius of the hospital, and 3) for whom we have adequate data on incidence of acute bacterial infections, risk factors for infection, and ability to comply with the treatment protocol (particularly hygiene).

-

Exclusion Criteria: Don't meet inclusion criteria.

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00139100

Locations
Haiti
Hopital Ste. Croix
Leogane, Haiti
Sponsors and Collaborators
Procter and Gamble
Ste. Croix Hospital, Leogane, Haiti
Investigators
Principal Investigator: David G Addiss, MD CDC/NCID/DPD
  More Information

Study ID Numbers: CDC-NCID-2822
Study First Received: August 29, 2005
Last Updated: October 23, 2008
ClinicalTrials.gov Identifier: NCT00139100  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Lymphatic filariasis
Elephantiasis, Filarial
Skin Diseases
Filariasis
Nematode Infections
Inflammation
Lymphedema
Lymphatic Diseases
Cellulitis
Skin Diseases, Infectious
Connective Tissue Diseases
Suppuration
Parasitic Diseases
Helminthiasis

Additional relevant MeSH terms:
Spirurida Infections
Pathologic Processes
Infection
Secernentea Infections

ClinicalTrials.gov processed this record on January 16, 2009